Celadon Pharmaceuticals PLC (GB:CEL) has released an update.
Celadon Pharmaceuticals PLC, a UK-based company specializing in cannabis-based medicines, has announced the upcoming admission of 238,095 new ordinary shares to AIM, with trading expected to commence on 19 July 2024. The final installment of shares will be admitted on 12 August 2024, bringing the total issued share capital to 66,220,807 Ordinary Shares. Celadon, with its EU-GMP approved 100,000 sq. ft facility, focuses on chronic pain and autism treatments and owns a Home Office license for commercial cannabis product supply.
For further insights into GB:CEL stock, check out TipRanks’ Stock Analysis page.
